Will vaccination against human papillomavirus prevent eye disease? A review of the evidence

British Journal of Ophthalmology

Volumn 92, Issue 4, 2008, Pages 460-465

  Hughes, D S ^a   Powell, N ^b   Fiander, A N ^b  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CARCINOGENESIS; CLINICAL TRIAL; EYE CANCER; EYE DISEASE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNIZATION; LIFE CYCLE; PAPILLOMA VIRUS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; EYE INFECTIONS, VIRAL; EYE NEOPLASMS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 41849114553     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.135038     Document Type: Review

References (57)

1. Wile UJ, Kingery LB. The etiology of common warts. JAMA 1919;73:529-39.
2. Rous P, Beard JW. Carcinomatous changes in virus-induced papillomas of the skin of rabbits. Proc Soc Exp Biol Med 1934;32:578-80.
3. Modis Y, Trus BL, Harrison SC. Atomic model of the papillomavirus capsid. EMBO J 2002;21:4754-62.
4. Crawford LV, Crawford EM. A comparative study of polyoma and papilloma viruses. Virology 1963;21:258-63.
5. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999;111:581-7.
6. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
7. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
8. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
9. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis 2002;186:462-9.
10. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
11. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003;307:1-11.
12. Doorbar J, Sterling J. The biology of human papillomaviruses. In: Tyring JSS, ed. Human papillomaviruses: clinical and scientific advances. London: Arnold, 2001:10-23.
13. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
14. Harper D, Franco E, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
16. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
17. Garland SM, Hernandez-Avila M, Wheeler SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
18. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
19. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
20. Halpert R, Fruchter RG, Sedlis A, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251-8.
21. Braun L. Role of human immunodeficiency virus infection in the pathogenesis of human papillomavirus-associated cervical neoplasia. Am J Pathol 1994;144:209-14.
22. Hong K, Greer CE, Ketter N, et al. Isolation and characterization of human papillomavirus type 6 specific T cells infiltrating genital warts. J Virol 1997;71:6427-32.
23. Nakagawa M, Stites DP, Farhat S, et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997;175:927-31.
24. de Jong A, van der Burg SH, Kwappenberg KM, et al. Freguent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9.
25. Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41.
26. Ashrafi GH, Brown DR, Fife KH, et al. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 2006;120:208-11.
27. Matthews K, Leong CM, Baxter L, et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003;77):8378-85.
28. Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987;161:259-61.
29. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995;69:2989-97.
30. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;244:76-9.
31. Dyson N, Howley PM, Münger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
32. DiPaolo JA, Woodworth CD, Popescu NC, et al. HSV-2-induced tumorigenicity in HPV16-immortalized human genital keratinocytes. Virology 1990;177:777-9.
33. Garrett LR, Perez-Reyes N, Smith PP, et al. Interaction of HPV-18 and nitrosomethylurea in the induction of squamous cell carcinoma. Carcinogenesis 1993;14:329-32.
34. Gloss B, et al. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J 1987;6:3735-43.
35. Kiire CA, Dhillon B. The aetiology and associations of conjunctival intraepithelial neoplasia. Br J Ophthalmol 2006;90:109-13.
36. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
37. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71.
38. Waller J, Marlow LA, Wardle J. Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarkers Prev 2006;15:1257- 61.
39. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007;45:107-14.
40. Raffle AE. Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ 2007;335:375-7.
41. Raffle AE. Human papillomavirus vaccine policy. Lancet 2007;369:367-8.
42. IARC. Human papillomaviruses. 2006. http://monographs.iarc.fr/ENG/ Meetings/ vol90.php (accessed 10 Jan 2008).
43. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
44. Odrich MG, Jakobiec FA, Lancaster WI, et al. A spectrum of bilateral squamous conjunctival tumors associated with human papillomavirus type 16. Ophthalmology 1991;98:628-35.
45. Saegusa M, Takano Y, Hashimura M, et al. HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma. J Clin Pathol 1995;48:1106-10.
46. Nakamura Y, Mashima Y, Kameyama K, et al. Detection of human papillomavirus infection in squamous tumours of the conjunctiva and lacrimal sac by immunohistochemistry, in situ hybridisation, and polymerase chain reaction. Br J Ophthalmol 1997;81:308-13.
47. Tabrizi SN, McCurrach FE, Drewe RH, et al. Human papillomavirus in corneal and conjunctival carcinoma. Aust N Z J Ophthalmol 1997;25:211-15.
48. Karcioglu ZA, Issa TM. Human papilloma virus in neoplastic and non-neoplastic conditions of the external eye. Br J Ophthalmol 1997;81:595-8.
49. Dushku N, Hatcher SL, Albert DM, et al. p53 expression and relation to human papillomavirus infection in Pingueculae, pterygia, and limbal tumors. Arch Ophthalmol 1999;117:1593-9.
50. Palazzi MA, Erwenne CM, Villa LL. Detection of human papillomavirus in epithelial lesions of the conjunctiva. Sao Paulo Med J 2000;118:125-30.
51. Toth J, Karcioglu ZA, Moshfeghi AA, et al. The relationship between human papillomavirus and p53 gene in conjunctival squamous cell carcinoma. Cornea 2000;19:159-62.
52. Detorakis ET, Sourvinos G, Spandidos DA. Detection of herpes simplex virus and human papilloma virus in ophthalmic pterygium. Cornea 2001;20:164-7.
53. Sjo NC, Heegaard S, Prause JU, et al. Human papillomavirus in conjunctival papilloma. Br J Ophthalmol 2001;85:785-7.
54. Gallagher MJ, Giannoudis A, Herrington CS, et al. Human papillomavirus in pterygium. Br J Ophthalmol 2001;85:782-4.
55. Eng HL, Lin TM, Chen SY, et al. Failure to detect human papillomavirus DNA in malignant epithelial neoplasms of conjunctiva by polymerase chain reaction. Am J Clin Pathol 2002;117:429-36.
56. Minchiotti S, Masucci L, Serapiao Dos Santos M, et al. Conjunctival papilloma and human papillomavirus: identification of HPV types by PCR. Eur J Ophthalmol 2006;16:473-7.
57. Sjo NC, von Buchwald C, Cassonnet P, et al. Human papillomavirus in normal conjunctival tissue and in conjunctival papilloma: types and frequencies in a large series. Br J Ophthalmol 2007;91:1014-15.